| Autor: |
Willson VJ; Department of Drug Development Metabolism and Bioanalysis, AstraZeneca R&D Charnwood, Loughborough, Leics., UK. viv.willson@astrazeneca.com, Lockley WJ, Mather A, Singh J, Gilbert CM, Bayliss MA, Wilkinson D |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2000 Nov; Vol. 23 (6), pp. 947-54. |
| DOI: |
10.1016/s0731-7085(00)00374-5 |
| Abstrakt: |
A dissociation-enhanced lathanide fluorescence immunoassay (DELFIA) method has been developed for the determination of AR-C68397XX, a novel respiratory therapeutic agent, in human plasma. The method is a 'direct' immunoassay and provides an alternative to the solid phase extraction RIA described in a previous publication, which employs the same specific antiserum. The DELFIA method is suitable for the determination of the analyte at pg ml(-1) concentrations. The non-isotopic label was prepared by complexation of a DTPA derivative of AR-C68397XX with free europium cation (Eu3+). Plasma samples were diluted at least 5-fold prior to analysis to eliminate matrix interference. The calibration range is 10-2000 pg ml(-1), and the LOQ of the method is 50 pg ml(-1) using 50 microl of diluted human plasma sample. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect